A neurotrophic peptide mixture derived from porcine brain proteins — widely approved for stroke and Alzheimer's globally.
Cerebrolysin is a mixture of low-molecular-weight neuropeptide fragments and amino acids derived from porcine brain proteins through enzymatic proteolysis. It contains approximately 25% active peptide fractions and 75% amino acids. The active peptide components are believed to cross the blood-brain barrier and exert neurotrophic effects similar to naturally occurring neurotrophic growth factors.
Developed in Austria by Ever Pharma GmbH (formerly EBEWE Pharma), cerebrolysin has been used clinically since the 1970s and is approved in over 40 countries including China, Russia, Germany, and multiple Asian and Eastern European nations. It is notable for being a complex biological mixture rather than a single defined molecule — making it difficult to study by conventional pharmaceutical methods.
The active peptide fractions in cerebrolysin appear to mimic the effects of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and other neurotrophic factors — promoting neuronal survival, neuroplasticity, and synaptic function. Administration is IV or IM, typically in courses of 10-30 daily infusions.
Multiple randomized controlled trials have demonstrated modest but statistically significant benefits in acute ischemic stroke recovery and Alzheimer's disease. A Cochrane systematic review found favorable effects in Alzheimer's patients. The CARS trial (China Cerebrolysin and Recovery after Stroke) was a large randomized trial showing efficacy in acute stroke.
Mechanistic research demonstrates cerebrolysin promotes neuroplasticity, reduces neuroinflammation, inhibits apoptosis (programmed cell death) in neurons, and may facilitate clearance of amyloid beta (implicated in Alzheimer's). These mechanisms align with observed clinical effects.
📚 Key Reference: PMID: 17199021 (Cochrane review Alzheimer's), PMID: 27577668 (CARS stroke trial)
Generally well-tolerated in clinical use over decades. Most common side effects: mild GI disturbances, dizziness, headache, fever with rapid IV infusion. Rare serious adverse events. Contraindicated in epilepsy (theoretical seizure risk), severe renal failure, pregnancy. As a porcine-derived product, prion disease risk is theoretical but considered negligible based on manufacturing processes. Consult your provider.
NOT FDA-approved in the US. Approved in 40+ countries including Austria, Russia, China, Germany, and most of Eastern Europe and Asia. In the US, available through compounding pharmacies or for personal import. Evidence base is solid but mixed quality by Western standards.